COMP <GO>
ANNX vs HELP // EV/EBITDA & P/E VALUATION
Annexon Inc. (NASDAQ) VS. Helus Pharma Inc. (NASDAQ) • 15-METRIC TALLY: ANNX 1
— HELP 1
■ METRIC PARITY
LAST: $4.01 (-0.74%) • MKT CAP: $760.2M
valuation
—
LAST: $10.71 (-1.83%) • MKT CAP: $782.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANNX VS. HELP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANNX | HELP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -24.53% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.4 | 44.7 | +7.72 | ANNX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $760.2M | $782.5M | -$22.3M | HELP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANNX REV | HELP REV | ANNX GROSS % | HELP GROSS % | ANNX FCF | HELP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$186.5M | — |
| FY 2024 | $0 | — | — | — | -$118.0M | — |
| FY 2023 | $0 | — | — | — | -$121.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANNX // BETA —
HELP // BETA —